Latest News

The listing below shows our latest News Items and is updated regularly.  If you wish to post a news item please select the 'Post News' button on the right.  The displayed news feed starts on 1st August 2016.  Older items can be found here.

To 'Post Your News' use the button at the top right.



AMSBIO: Targeted Protein Degradation for Drug Discovery

AMSBIO has introduced a new range of homogeneous proximity assays, critical enzymes and small molecule inhibitors to assess the chemical adaptor function of Proteolysis Targeting Chimeras (PROTACs).

Read the rest of entry »

Immunocore: Detailed Review of Tebentafusp (IMCgp100) in Metastatic Uveal Melanoma Published in Issue of Cancers

(Oxfordshire, UK and Pennsylvania and Maryland, US, 16 July 2019) Immunocore Limited, a leading T Cell Receptor (TCR) biotechnology company, today announce the publication of “Tebentafusp: T Cell Redirection for the Treatment of Metastatic Uveal Melanoma” in a special issue on uveal melanoma in Cancers, an international, peer-reviewed monthly journal.

Read the rest of entry »

Inivata Signs Distribution Agreement with IPS Genomix for InVision® Genomic Tests in the Middle East and Africa

Research Triangle Park, NC, USA and Cambridge, UK, and Dubai, UAE , July 16, 2019 -- Inivata, a leader in liquid biopsy, has signed a distribution agreement with IPS Genomix, part of the IPS Group,  to provide cancer patients and partners in the Middle East and Africa with access to its InVisionFirst®-Lung and InVisionSeq™ liquid biopsy tests.

Read the rest of entry »

AMSBIO Biotinylated Hyaluronan Binding Protein (biotin-HABP) Reagent Cited In Groundbreaking Cancer Resistance Investigation 

AMSBIO reports on the pioneering research published** in a collaborative effort between researchers in the School of Engineering, University of Newcastle and Department of Pharmacology, University of Cambridge, UK that has cited Biotinylated Hyaluronan Binding Protein (biotin-HABP) supplied by the company in its investigation into the cancer resistance of the naked mole-rat (NMR).

Read the rest of entry »

The Biosphere hosts workshop to generate ideas to address unmet clinical needs in children’s cancer care

Despite improving survival rates, cancer is the leading cause of death in children and young people. There is a growing need for technology to support children and young people with cancer, as well as to support health care professionals to provide optimal care.

Read the rest of entry »

Invest Newcastle show off the region’s innovative life science sector to Cuban visitors

Invest Newcastle has welcomed a senior Cuban life science business delegation to the region for a two-day visit. They used this opportunity to show off the city’s life science strengths and world-leading universities.

Read the rest of entry »

AMSBIO: Extensive CAR-T Cell Range for Research & Immunotherapy

AMSBIO announce new, best-in-class CAR-T cells, engineered CAR-T target cells, PBMC, cell media and activation beads in response to the rapid growth in research on the therapeutic uses of CAR-T cells.

Read the rest of entry »

Arecor: Signs A New Formulation Evaluation Agreement With An Existing Partner, A Major Global Pharmaceutical Company

Arecor Limited, the specialty pharmaceutical company, leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, today announces that it has signed a further collaboration with a major global pharmaceutical company.

Read the rest of entry »

Invest Newcastle: Global Head of Neuroscience Discovery marks the official launch of The Biosphere

On Thursday 4 July Dr. Fiona Marshall, Global Head of Neuroscience Discovery, MSD visited Newcastle to mark the official launch of The Biosphere. Located at Newcastle Helix, The Biosphere is a specialist lab facility tailored to commercialisation of life sciences.  It provides biology and chemistry laboratories and high-quality office space. 

Read the rest of entry »

Physiomics: Agreement with Bicycle and Cancer Research UK

Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is pleased to announce that it has signed an agreement to work with Bicycle Therapeutics and Cancer Research UK.

Read the rest of entry »

Pages: Previous1234567...57NextReturn Top

Search Posts

News Policy

OBN aims to provide sector NEWS that is relevant to our Membership. We filter information from a variety of sources, publish items ourselves and will publish items of News from our Members. Press releases about OBN can be found here.